Equities

Sonoma Pharmaceuticals Inc

Sonoma Pharmaceuticals Inc

Actions
Health CareMedical Equipment and Services
  • Price (USD)3.83
  • Today's Change-0.47 / -10.93%
  • Shares traded1.30m
  • 1 Year change-78.24%
  • Beta1.3389
Data delayed at least 15 minutes, as of Sep 19 2024 21:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 18-Jul-24
  • 15-Aug-24
  • 12-Sep-24
Select bar for recommendation details.
Recommendations12-Sep-24
Buy1
Outperform0
Hold0
Sell0
Strong Sell0

Share price forecast in USD

The one analyst offering a 12 month price target expects Sonoma Pharmaceuticals Inc share price to rise to 30.00 in the next year from the last price of 3.83.
High683.3%30.00
Med683.3%30.00
Low683.3%30.00

Earnings history & estimates in USD

On Aug 08, 2024, Sonoma Pharmaceuticals Inc reported 1st quarter 2025 losses of -1.40 per share.
The next earnings announcement is expected on Nov 11, 2024.
Average growth rate+21.21%
Sonoma Pharmaceuticals Inc reported annual 2024 losses of -10.60 per share on Jun 17, 2024.
Average growth rate+22.38%
More ▼

Revenue history & estimates in USD

Sonoma Pharmaceuticals, Inc. had 1st quarter 2025 revenues of 3.39m. This missed the 3.94m estimate of the one analyst following the company. This was 1.05% below the prior year's 1st quarter results.
Average growth rate+0.70%
Sonoma Pharmaceuticals, Inc. had revenues for the full year 2024 of 12.74m. This was 4.05% below the prior year's results.
Average growth rate+2.42%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.